Who are tacrolimus + steroid's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sandimmune, CYCLOSPORINE, Maintenance of immediate-release tacrolimus, Tacrolimus (TAC), Basiliximab, Tacrolimus, MMF, Prednisolon, Elidel-Creme.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tacrolimus-steroid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

tacrolimus + steroid — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

tacrolimus + steroid (tacrolimus + steroid) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: immunosuppressant. Area: Immunology.

phase 3 immunosuppressant calcineurin Immunology Small molecule Live · refreshed every 30 min

Target snapshot

tacrolimus + steroid (tacrolimus + steroid) — Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan. Tacrolimus is an immunosuppressant that inhibits calcineurin, a protein phosphatase involved in the activation of T-lymphocytes, while steroids reduce inflammation and suppress the immune system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
tacrolimus + steroid TARGET	tacrolimus + steroid	Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan	phase 3	immunosuppressant	calcineurin
Sandimmune	cyclosporine	Novartis AG (originally Sandoz)	marketed	Calcineurin inhibitor (immunosuppressant)	Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2	1983-11-14
CYCLOSPORINE	CYCLOSPORINE		marketed	Calcineurin Inhibitor Immunosuppressant [EPC]	calcineurin	1983-01-01
Maintenance of immediate-release tacrolimus	Maintenance of immediate-release tacrolimus	Massachusetts General Hospital	marketed	Calcineurin inhibitor	Calcineurin (via FKBP12 binding)
Tacrolimus (TAC)	Tacrolimus (TAC)	ITB-Med LLC	marketed	Calcineurin inhibitor	Calcineurin (protein phosphatase 2B)
Basiliximab, Tacrolimus, MMF, Prednisolon	Basiliximab, Tacrolimus, MMF, Prednisolon	University Hospital Freiburg	marketed	Immunosuppressive combination regimen	IL-2 receptor (basiliximab), calcineurin (tacrolimus), IMPDH (MMF), glucocorticoid receptor (prednisolone)
Elidel-Creme	Elidel-Creme	Technische Universität Dresden	marketed	Calcineurin inhibitor (topical immunosuppressant)	Calcineurin; macrophilin-12

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-11-03 — Sandimmune · 8298568 · Formulation · US
2029-06-02 — Sandimmune · 9132071 · Formulation · US
2030-12-13 — Sandimmune · 8614178 · Formulation · US
2031-02-25 — Sandimmune · 8292129 · Formulation · US
2032-04-16 — Sandimmune · 8561859 · Formulation · US
2033-08-23 — Sandimmune · 8980839 · Formulation · US
2033-08-23 — Sandimmune · 10441630 · Formulation · US
2033-08-23 — Sandimmune · 9937225 · Formulation · US
2034-02-07 — Sandimmune · 9676525 · Formulation · US
2034-05-11 — Sandimmune · 9669974 · Formulation · US
2036-09-29 — Sandimmune · 12496326 · Method of Use · US
2037-02-28 — Sandimmune · 11951153 · Method of Use · US
2037-02-28 — Sandimmune · 10918694 · Formulation · US
2037-09-22 — Sandimmune · 10813976 · Formulation · US
2038-11-20 — Sandimmune · 11154513 · Formulation · US
2039-10-11 — Sandimmune · 11413323 · Method of Use · US
2042-04-01 — Sandimmune · 12059449 · Formulation · US

Sponsor landscape (immunosuppressant class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Centre Hospitalier Universitaire, Amiens · 1 drug in this class
DH Bio Co., Ltd. · 1 drug in this class
Glenmark Pharmaceuticals Ltd. India · 1 drug in this class
Palvella Therapeutics, Inc. · 1 drug in this class
Pfizer · 1 drug in this class
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · 1 drug in this class
University of California, San Francisco · 1 drug in this class
Vanderbilt-Ingram Cancer Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). tacrolimus + steroid — Competitive Intelligence Brief. https://druglandscape.com/ci/tacrolimus-steroid. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing